The transient receptor potential cation channel subfamily V member 1 (TRPV1) has recently gained attention as a potential target for the development of novel antineoplastic agents. It has been reported that the TRPV1 agonist arvanil has effective antiproliferative effects in studies using human breast cancer cells lines. In an extension of this research we have evaluated the IC50 values of arvanil in the prostate cancer cell lines PPC-1 (primary) and TSU (metastatic). Both TSU and PPC-1 cell lines are sensitive to treatment with arvanil. These results prompted the investigations into the changes in âcell metabolismâ associated with prostate cancer progression and the effect of arvanil treatment. Thus, employed High Resolution Magic-Angle Spinning (HR-MAS) NMR spectroscopy on whole cells to determine the differences in the relative amount of cell metabolites and changes in small molecule metabolism following treatment of the TSU and PPC-1 cells with arvanil. (Wei Li, The Effect of Arvanil on Prostate Cancer Cells Studied by Whole Cell High Resolution Magic Angle Spinning NMR)
Last date updated on April, 2024